Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00548093 · ClinicalTrials.gov registry record · Phase 2
PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
NCT00548093 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 66 participants.
The verdict
NCT00548093, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
Study Summary
To assess the antitumor efficacy measured by the objective response rate of oral PF-00299804 taken daily, as single agent in patients with advanced NSCLC who failed at least one chemotherapy + erlotinib.
Interventions
- DRUG PF-00299804
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2008-04-29 |
| Est. Completion | 2012-06-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00548093
The ClinicalTrials.gov registry entry for NCT00548093 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-00299804 is the first listed.
NCT00548093 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00548093 about?
NCT00548093 is a clinical study titled "PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib". To assess the antitumor efficacy measured by the objective response rate of oral PF-00299804 taken daily, as single agent in patients with advanced NSCLC who failed at least one chemotherapy + erlotinib.
What is the current status of trial NCT00548093?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2008-04-29. Estimated completion is 2012-06-11.
What interventions are being tested in trial NCT00548093?
The interventions under investigation include: PF-00299804 (DRUG).
Who is sponsoring clinical trial NCT00548093?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.